Your AI-Trained Oncology Knowledge Connection!
Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.
A post hoc analysis of the COU-AA-302 clinical trial suggests that docetaxel has antitumor activity as first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.
Aspirin’s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.
The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.
Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.
Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.
The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.
The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.
Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.
Breast cancer recurrence was similar whether postmenopausal women with ductal carcinoma in situ received anastrozole or tamoxifen for 5 years following local excision in the IBIS-II trial.
Patient reports of their experiences with taking either tamoxifen or anastrozole can help clinicians decide which one to recommend to individual women, new research has found.
Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.
T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.
Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.
Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).
The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.
Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.
Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.
The risk of complications from mastectomy plus reconstruction was increased by two-fold compared with lumpectomy plus whole breast irradiation, after adjustment for other treatment differences.
Women who opt for breast-conserving therapy and radiation to treat their early-stage breast cancer are about 20% more likely to be alive after 10 years compared with their counterparts who had mastectomy.
Reuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.
Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.
Adding carboplatin to neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.
Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.
Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.
Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.
Premenopausal women with high-risk breast cancer of the luminal A subtype derive no benefit from adjuvant chemotherapy.
A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.
